Jefferies Financial Group Acquires Stake in PTC Therapeutics

Investment firm buys over 1.5 million shares of biopharmaceutical company

Mar. 9, 2026 at 10:20am

Got story updates? Submit your updates here. ›

Jefferies Financial Group Inc. has acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT), purchasing 1,584,678 shares of the biopharmaceutical company's stock during the third quarter. The investment, valued at approximately $97.2 million, makes Jefferies one of the largest shareholders of PTC Therapeutics, owning about 1.97% of the company.

Why it matters

This significant investment by a major financial institution highlights the potential growth and value that Wall Street sees in PTC Therapeutics and its pipeline of rare disease treatments. The acquisition could signal increased institutional interest and confidence in the company's future prospects.

The details

According to a recent 13F filing, Jefferies Financial Group bought the 1.58 million shares of PTC Therapeutics, making it the 7th largest holding in the firm's investment portfolio. PTC Therapeutics is a biopharmaceutical company focused on developing treatments for rare genetic disorders, including its approved product Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.

  • Jefferies Financial Group acquired the PTC Therapeutics shares during the 3rd quarter of 2026.

The players

Jefferies Financial Group Inc.

A global investment banking firm that provides a full range of investment banking, advisory, sales and trading, research and asset management services.

PTC Therapeutics, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare genetic disorders, including its approved product Translarna.

Got photos? Submit your photos here. ›

The takeaway

This substantial investment by Jefferies Financial Group underscores the growing investor interest and confidence in PTC Therapeutics' ability to develop innovative treatments for rare diseases. The acquisition could signal a broader trend of increased institutional backing for specialty pharmaceutical companies tackling high unmet medical needs.